Accelerated Approval: US FDA Explains ‘Reasonably Likely’ Determination Criteria

 
• By Sue Sutter
  
Sea view
A new draft guidance clarifies how the FDA decides when an effect on a surrogate endpoint is reasonably likely to predict clinical benefit. (Shutterstock)

More from Review Pathways

More from Approval Standards